| domain | key finding | quantitative evidence | suggested ontology terms | evidence/source year |
|---|---|---|---|---|
| disease scope | Isolated anophthalmia-microphthalmia is best treated as a congenital phenotype spectrum within MAC; “isolated/non-syndromic” is a phenotype qualifier, not a single molecular disorder, and many causative genes also produce syndromic disease | Combined MAC prevalence ~1–4/10,000 live births; A/M contributes 3–12% of childhood visual impairment/blindness estimates in reviews/cohorts | anophthalmia, microphthalmia, congenital eye malformation, non-syndromic phenotype qualifier | 2019–2023 (pqac-00000000, pqac-00000002) |
| definitions | Anophthalmia = absence of visible globe/eye tissue; microphthalmia = axial length ≥2 SD below age-adjusted mean; severe microphthalmia includes very short axial length and small cornea | Adult axial length <21 mm; newborn <14 mm in one review, and operational clinic thresholds <16 mm at birth, <19 mm at 12 months, <21 mm in adults in a prospective cohort | HP:0000528 Anophthalmia; HP:0000568 Microphthalmia; severe microphthalmia; simple microphthalmia; complex microphthalmia | 2019, 2023 (pqac-00000001, pqac-00000006) |
| onset/natural history | Disorder is congenital and usually recognized neonatally/infancy; laterality is variable and asymmetry is common | Mean cohort age 13 years in prospective MAC clinic; severe forms present at birth; both unilateral and bilateral disease occur | congenital onset, unilateral, bilateral, asymmetric involvement | 2019, 2023 (pqac-00000000, pqac-00000006) |
| major ocular phenotypes | Core phenotype is absent or small eye; additional ocular anomalies may occur even in apparently isolated cases, especially coloboma, cataract, glaucoma, retinal dystrophy/detachment | In a prospective cohort, 44% had complex ocular features; retinal detachment 9%; no diagnosis in exclusive coloboma subgroup in that cohort | HP:0000528 Anophthalmia; HP:0000568 Microphthalmia; coloboma; cataract; glaucoma; retinal detachment | 2019, 2023 (pqac-00000003, pqac-00000004, pqac-00000009) |
| non-ocular qualifier | “Isolated” requires absence of extra-ocular findings at ascertainment, but some genes show incomplete penetrance/variable expressivity so systemic findings may emerge or be subtle | In a pediatric cohort, isolated A/M occurred in 16/35, while 19/35 had somatic/psychomotor/neuroradiologic/genetic pathology | non-syndromic, syndromic, variable expressivity, incomplete penetrance | 2022 (pqac-00000012) |
| core genes: AD | Major dominant genes include SOX2 and OTX2; both are dosage-sensitive developmental transcription factors and may cause isolated or syndromic disease | SOX2: 10–15% of all A/M, 15–40% of bilateral severe AM; OTX2: ~0.7–10% or 2–8% of AM in reviews; SOX2+OTX2 together account for ≥60% of bilateral severe cases in one review | SOX2, OTX2, haploinsufficiency, autosomal dominant, de novo, mosaicism | 2019 (pqac-00000008, pqac-00000009, pqac-00000011) |
| core genes: AR | Important recessive genes include RAX, VSX2, ALDH1A3, and some MAB21L2 cases; these often present with bilateral severe disease | RAX biallelic variants: ~2–3% of AM; ALDH1A3 responsible for ~11% of recessively inherited severe developmental eye anomalies; all 9 affected individuals in Kesim 2023 had bilateral A/M | RAX, VSX2, ALDH1A3, MAB21L2, autosomal recessive, bilateral severe A/M | 2019–2023 (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000016) |
| additional genes / CNVs | Other genes and copy-number changes contribute, including FOXE3, PAX6, BMP7, BCOR, KMT2D, EPHA2, MAB21L2 and large deletions; some are more often syndromic but can appear in isolated MAC presentations | Prospective cohort solved cases involved SOX2, PAX6, KMT2D, EPHA2, MAB21L2, ALDH1A3, BCOR, FOXE3 plus deletions on chromosomes 10, 11 and X; chromosomal anomalies reported up to ~15% overall | FOXE3, PAX6, BMP7, BCOR, KMT2D, EPHA2, CNV, chromosomal deletion | 2019, 2023 (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000010) |
| inheritance nuances | De novo disease, parental mosaicism, incomplete penetrance, and variable expressivity are common and complicate counseling; unilateral vs bilateral severity can differ within gene/family | SOX2 mostly de novo with parental mosaicism reported; OTX2 ~50% de novo with high non-penetrance; MAB21L2 shows AD and AR examples with dominant-negative effect proposed for monoallelic missense variants | incomplete penetrance, variable expressivity, gonosomal mosaicism, dominant negative, haploinsufficiency | 2019 (pqac-00000008, pqac-00000009, pqac-00000010) |
| developmental pathways | Core upstream mechanism is disruption of eye-field specification and optic vesicle/cup morphogenesis involving SOX2-OTX2-RAX/PAX6/SIX3 networks, SHH patterning, WNT/FGF balance, BMP signaling, and retinoic acid metabolism | Reviews identify conserved transcription factor and signaling pathway modules rather than a single pathway; PTCH1 variants may contribute up to 10% of ocular developmental anomalies in one sequencing study | eye field specification, optic vesicle formation, optic cup morphogenesis, SHH signaling, WNT signaling, BMP signaling, retinoic acid signaling | 2015–2020 (pqac-00000022, pqac-00000023, pqac-00000024) |
| mechanistic examples | SOX2/OTX2 coregulate RAX; PTCH1 links SOX2 network to SHH; ALDH1A3 and STRA6 impair retinoic acid biology; VSX2 loss shifts neural retina toward RPE fate with WNT upregulation | PTCH1 study estimated contribution up to 10% of ocular developmental anomalies; VSX2 hiPSC optic vesicles showed WNT11/BMP8A up, FGF19 down, and rescue with WNT inhibition in cited model literature | RAX regulation, PTCH1, SHH effector, ALDH1A3, STRA6, neural retina, retinal pigment epithelium | 2016–2020 (pqac-00000018, pqac-00000019, pqac-00000020, pqac-00000023) |
| anatomy / tissues / cells | Primary structures affected are globe, optic vesicle/cup, neuroretina, retinal pigment epithelium, lens placode, and ventral optic cup; retinal progenitor cells are a key implicated cell population | ALDH1A3/Raldh3 knockout data support ventral retina shortening; RAX and VSX2 are tied to retinal progenitor establishment/specification | eye globe, optic vesicle, optic cup, neuroretina, retinal pigment epithelium, lens placode, retinal progenitor cell | 2019–2020 (pqac-00000009, pqac-00000019, pqac-00000020) |
| epidemiology / demographics | Rare congenital disorder spectrum with variable ascertainment by registry and clinic; childhood blindness burden is substantial | Prevalence estimates range ~1–3 or 1–4 per 10,000 live births; one prospective clinic cohort was 60% female but not population-representative | rare disease, congenital anomaly epidemiology | 2019, 2023 (pqac-00000000, pqac-00000002, pqac-00000006) |
| diagnostics: clinical | Diagnosis is clinical plus imaging/biometry, with classification into simplex, mixed, complex, and syndromic vs non-syndromic; neuroimaging is important when bilateral or developmental concerns exist | Brain MRI abnormalities in 7/28 scanned prospective MAC patients; 6/7 with intracranial findings had bilateral MAC; neuroimaging abnormalities in 14/20 in the pediatric QoL cohort, corpus callosum dysgenesis 6/20 | ocular examination, axial length biometry, orbital MRI, neuroimaging, phenotype classification | 2022, 2023 (pqac-00000006, pqac-00000007, pqac-00000012) |
| diagnostics: molecular | Testing strategy should include gene panel/exome/genome plus CNV analysis; WGS/WES improves yield but many cases remain unsolved, especially milder/unilateral disease | >50% remain undiagnosed even after WES/WGS in review; clinic diagnostic rates ~28–34%; WGS yield 15.7% for MAC in Genomics England cohort; cES in nonisolated MAC 32.3–48.1% | gene panel, WES, WGS, chromosomal microarray, CNV analysis, HPO phenotyping | 2019–2024 (pqac-00000001, pqac-00000004, pqac-00000013, pqac-00000017) |
| diagnostic yield in real-world care | Both unilateral and bilateral cases merit testing; yields are not negligible in unilateral disease and CNVs can be important | Prospective Moorfields cohort: 28% overall solved among tested families, 33% in both unilateral and bilateral cohorts; aCGH 3/3, WGS 4/17, targeted panel 3/18, single-gene 1/1 | routine genetic testing, bilateral disease, unilateral disease, array CGH | 2023 (pqac-00000004, pqac-00000005, pqac-00000007) |
| management / real-world implementation | No disease-restoring therapy is established; management is supportive, visual rehabilitation-focused, and often includes multidisciplinary genetics/ophthalmology care and socket/prosthetic planning | Review explicitly states “currently no treatments are available” for microphthalmia; in prospective care, 66% did not require custom prostheses and 7/50 were advised customized contact shells | supportive care, low vision care, ocular prosthesis, customized contact shell, multidisciplinary care, genetic counseling | 2021, 2023 (pqac-00000021, pqac-00000007) |
| prognosis / complications | Vision ranges from normal in fellow eye to blindness; complications depend on anatomy and associated anomalies; lifelong follow-up may be needed | In pediatric cohort, 10/35 were totally blind or had light perception; retinal detachment reported in 9% in prospective cohort and occurred from first to third decade | blindness, light perception only, retinal detachment, lifelong follow-up | 2022, 2023 (pqac-00000003, pqac-00000012) |
| quality of life | Health-related quality of life is reduced in affected children/families | Parent-reported PedsQL median total score 52.4 (range 22.6–100) in ages 2–12 | quality of life impairment, pediatric QoL | 2022 (pqac-00000012) |
| prevention / counseling | Primary prevention is limited because many cases are monogenic/de novo, but molecular diagnosis informs recurrence risk, prenatal options, and family counseling; environmental contributors are recognized but incompletely quantified for isolated Mendelian cases | Reviews note both genetic and environmental causes; mosaicism and incomplete penetrance materially affect recurrence-risk counseling | genetic counseling, recurrence risk, prenatal diagnosis, environmental teratogen assessment | 2019–2021 (pqac-00000001, pqac-00000021) |
| model organisms | Mouse, zebrafish, Xenopus and human iPSC optic vesicles/cups are leading models; they reproduce many but not all human phenotypes | Review notes mouse, zebrafish and Xenopus as main systems; hiPSC optic cups effectively modeled VSX2-related microphthalmia; species differences limit direct translation | mouse model, zebrafish model, Xenopus model, hiPSC, optic vesicle organoid, optic cup organoid | 2020–2021 (pqac-00000019, pqac-00000020, pqac-00000021) |
| model-specific insights | Human iPSC models are particularly valuable for early human-specific fate defects and therapy screening, while animal models reveal conserved pathways and whole-organism effects | VSX2 null hiPSC vesicles showed WNT upregulation/RPE misexpression and pharmacologic rescue with WNT inhibition; zebrafish/CRISPR and mouse data support SOX2, PTCH1 and retinoid mechanisms | disease modeling, pathway rescue, human-specific developmental model | 2016–2020 (pqac-00000018, pqac-00000019, pqac-00000020) |


*Table: This compact table summarizes knowledge-base-ready findings for isolated anophthalmia-microphthalmia, including definitions, phenotypes, genes, mechanisms, diagnostics, care, prognosis, and models. It emphasizes that isolated A/M is a phenotypic category within a heterogeneous developmental eye-disorder spectrum rather than a single molecular entity.*